-
white matter. The network aims to strengthen the full translational pathway, from understanding disease mechanisms and developing disease models to preclinical therapy testing, clinical readiness and
-
, from understanding disease mechanisms and developing disease models to preclinical therapy testing, clinical readiness and patient-informed treatment priorities. To achieve this, POLARIS brings together
-
mechanisms and developing disease models to preclinical therapy testing, clinical readiness and patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy
-
generated nanobodies in vitro and in vivo, including their affinity, specificity, stability and modulatory effects. Investigating the biodistribution of nanobodies in in vivo models. Characterising
-
white matter. The network aims to strengthen the full translational pathway, from understanding disease mechanisms and developing disease models to preclinical therapy testing, clinical readiness and
-
white matter. The network aims to strengthen the full translational pathway from disease mechanisms and model development to preclinical therapy testing, clinical readiness and patient-informed treatment
-
mechanisms and model development to preclinical therapy testing, clinical readiness and patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology
-
; developing innovative data models in collaboration with a postdoctoral researcher and other consortium partners; identifying biomarker candidates for next-generation miniaturized screening assays; presenting
-
institutions and several industrial partners with extensive expertise in quantitative imaging, image analysis and imaging technology. By conducting research in both academic and industrial settings, PhD